Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13

Rhea-AI Summary

Celsion Corporation (NASDAQ: CLSN) will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 4:30 p.m. Eastern time. The presentation will be accessible live and on-demand through a provided link. The conference is scheduled from September 12-14, allowing for in-person meetings at the Lotte New York Palace Hotel. Celsion focuses on innovative cancer treatments, including immunotherapies and DNA therapies, with a pipeline featuring GEN-1, a DNA-based immunotherapy.

Positive

• Participation in a prominent investment conference may enhance visibility and investor interest.
• Focus on innovative cancer treatments positions the company favorably in the biotech sector.

Negative

• None.

LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 24^th Annual Global Investment Conference on September 13^th at 4:30 p.m. Eastern time. The presentation will available live and on-demand here.

As previously announced, the conference will be held September 12-14 with in-person participation at the Lotte New York Palace Hotel. Dr. Le Goff is also available for in-person meetings at the conference.

About Celsion Corporation

Celsion is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies, and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV-2. The company’s product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. Celsion also has two feasibility-stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anticancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection. For more information on Celsion, visit www.celsion.com.

Celsion Investor Contact

Jeffrey W. Church
Executive Vice President and CFO
609-482-2455
jchurch@celsion.com

# # #

FAQ

When is Celsion presenting at the H.C. Wainwright Global Investment Conference?

Celsion will present on September 13, 2022, at 4:30 p.m. Eastern time.

What is GEN-1 in Celsion's pipeline?

GEN-1 is a DNA-based immunotherapy aimed at treating ovarian cancer.

Where is the H.C. Wainwright conference being held?

The conference is at the Lotte New York Palace Hotel.

What types of therapies does Celsion focus on?

Celsion focuses on immunotherapies, DNA-based therapies, and nucleic acid vaccines.

Who is the CEO of Celsion Corporation?

Dr. Corinne Le Goff is the President and CEO of Celsion Corporation.